心房颤动的卒中预防
Stroke Prevention in Atrial Fibrillation.
作者信息
Katsnelson Michael, Koch Sebastian, Rundek Tatjana
机构信息
Department of Neurology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.
出版信息
J Atr Fibrillation. 2010 Oct 22;3(3):279. doi: 10.4022/jafib.279. eCollection 2010 Oct-Nov.
Abstract
Non-valvular atrial fibrillation is a common and from a neurological perspective the most significant cardiac arrhythmia with a growing world-wide incidence. It also carries a significant associated morbidity and mortality, with cardioembolic strokes arguably being the most disabling sequelae. This brief review will highlight the important studies and the latest treatment modalities available for stroke prevention in patients with non-valvular atrial fibrillation.
摘要
非瓣膜性心房颤动是一种常见的心律失常，从神经学角度来看，它是最重要的心律失常，在全球范围内的发病率呈上升趋势。它还伴有显著的相关发病率和死亡率，心脏栓塞性中风可以说是最致残的后遗症。这篇简短的综述将重点介绍非瓣膜性心房颤动患者预防中风的重要研究和最新治疗方法。
相似文献
1
Stroke Prevention in Atrial Fibrillation.
J Atr Fibrillation. 2010 Oct 22;3(3):279. doi: 10.4022/jafib.279. eCollection 2010 Oct-Nov.
2
Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks.
Cochrane Database Syst Rev. 2005 Oct 19;2005(4):CD001925. doi: 10.1002/14651858.CD001925.pub2.
3
[Italian Study on Atrial Fibrillation (SIFA): status report].
Cardiologia. 1993 Dec;38(12 Suppl 1):327-32.
4
Atrial Fibrillation in the Elderly: Who is at Risk?
Am J Geriatr Cardiol. 1998 Oct;7(5):13-23.
5
Causes of Ischemic Stroke in Patients with Non-Valvular Atrial Fibrillation.
Cerebrovasc Dis. 2016;42(3-4):196-204. doi: 10.1159/000445723. Epub 2016 Apr 26.
6
Blood pressure control versus atrial fibrillation management in stroke prevention.
Curr Hypertens Rep. 2015 Jun;17(6):553. doi: 10.1007/s11906-015-0553-1.
7
8
Cardioembolic stroke: an update.
Lancet Neurol. 2003 Mar;2(3):177-88. doi: 10.1016/s1474-4422(03)00324-7.
9
Atrial Fibrillation in the Elderly: A Review.
Am J Geriatr Cardiol. 1994 Mar;3(2):26-40.
10
Atrial fibrillation and stroke: clinical presentation of cardioembolic versus atherothrombotic infarction.
Int J Cardiol. 2000 Mar 31;73(1):33-42. doi: 10.1016/s0167-5273(99)00214-4.
引用本文的文献
1
Deep terminal negative of the P wave in V1 and incidence of ischemic stroke: The atherosclerosis risk in communities (ARIC) study.
J Electrocardiol. 2024 May-Jun;84:123-128. doi: 10.1016/j.jelectrocard.2024.03.016. Epub 2024 Apr 17.
2
Left Atrial Mechanical Dysfunction and the Risk for Ischemic Stroke in People Without Prevalent Atrial Fibrillation or Stroke : A Prospective Cohort Study.
Ann Intern Med. 2023 Jan;176(1):39-48. doi: 10.7326/M22-1638. Epub 2022 Dec 20.
3
Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation Treatment: Rural and Urban Trends in Medicare Beneficiaries.
Am J Cardiovasc Drugs. 2022 Mar;22(2):207-217. doi: 10.1007/s40256-021-00502-9. Epub 2021 Oct 11.
4
Refining Prediction of Atrial Fibrillation-Related Stroke Using the P-CHADS-VASc Score.
Circulation. 2019 Jan 8;139(2):180-191. doi: 10.1161/CIRCULATIONAHA.118.035411.
5
Abnormal P-Wave Axis and Ischemic Stroke: The ARIC Study (Atherosclerosis Risk In Communities).
Stroke. 2017 Aug;48(8):2060-2065. doi: 10.1161/STROKEAHA.117.017226. Epub 2017 Jun 16.
6
Processes and Recommendations for Creating mHealth Apps for Low-Income Populations.
JMIR Mhealth Uhealth. 2017 Apr 3;5(4):e41. doi: 10.2196/mhealth.6510.
本文引用的文献
1
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).
Eur Heart J. 2010 Oct;31(19):2369-429. doi: 10.1093/eurheartj/ehq278. Epub 2010 Aug 29.
2
3
New oral anticoagulant drugs in cardiovascular disease.
Thromb Haemost. 2010 Jul;104(1):49-60. doi: 10.1160/TH09-05-0327. Epub 2010 Jun 10.
4
The CHADS2 score for stroke risk stratification in atrial fibrillation--friend or foe?
Thromb Haemost. 2010 Jul;104(1):45-8. doi: 10.1160/TH09-11-0757. Epub 2010 May 10.
5
Are atrial fibrillation patients receiving warfarin in accordance with stroke risk?
Am J Med. 2010 May;123(5):446-53. doi: 10.1016/j.amjmed.2009.11.015.
6
Dabigatran challenges warfarin's superiority for stroke prevention in atrial fibrillation.
Stroke. 2010 Jun;41(6):1307-9. doi: 10.1161/STROKEAHA.110.584557. Epub 2010 Apr 15.
7
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.
Chest. 2010 Nov;138(5):1093-100. doi: 10.1378/chest.10-0134. Epub 2010 Mar 18.
8
Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Thromb Haemost. 2010 Mar;103(3):604-12. doi: 10.1160/TH09-07-0509. Epub 2010 Jan 13.
9
Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.
Chest. 2010 Feb;137(2):263-72. doi: 10.1378/chest.09-1584. Epub 2009 Sep 17.
10
New anticoagulants for atrial fibrillation.
Semin Thromb Hemost. 2009 Jul;35(5):515-24. doi: 10.1055/s-0029-1234147. Epub 2009 Sep 8.
Zotero 插件